Novartis AG ADR
$ 158.44
-0.25%
30 Jul - close price
- Market Cap 301,890,535,000 USD
- Current Price $ 158.44
- High / Low $ 158.55 / 156.46
- Stock P/E 24.14
- Book Value 20.18
- EPS 6.58
- Next Earning Report 2026-10-27
- Dividend Per Share $4.67
- Dividend Yield 2.97 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.30 %
- 52 Week High 165.43
- 52 Week Low 110.13
About
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Analyst Target Price
$155.37
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-21 | 2026-04-28 | 2026-02-04 | 2025-10-28 | 2025-07-17 | 2025-04-29 | 2025-01-31 | 2024-10-29 | 2024-07-18 | 2024-04-23 | 2024-01-31 | 2023-10-24 |
| Reported EPS | 2.41 | 1.65 | 2.03 | 2.25 | 2.42 | 2.28 | 1.98 | 2.06 | 1.97 | 1.8 | 1.53 | 1.74 |
| Estimated EPS | 2.2 | 1.65 | 2 | 2.31 | 2.37 | 2.17 | 1.76 | 1.93 | 1.86 | 1.68 | 1.66 | 1.74 |
| Surprise | 0.21 | 0 | 0.03 | -0.06 | 0.05 | 0.11 | 0.22 | 0.13 | 0.11 | 0.12 | -0.13 | 0 |
| Surprise Percentage | 9.5455% | 0% | 1.5% | -2.5974% | 2.1097% | 5.0691% | 12.5% | 6.7358% | 5.914% | 7.1429% | -7.8313% | 0% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-27 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | 2.2 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Apr 2025 | Apr 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-16 | 2025-04-25 | 2024-04-19 | 2023-03-20 | 2022-03-17 | 2021-03-15 | None | None | None | None |
| Amount | $4.772961 | $3.99399 | $3.7395445 | $3.4693612 | $3.3574492 | $3.3783783 | $3.0424917 | $2.865 | $2.977 | $2.717759 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVS
2026-07-30 16:09:10
Private equity firm ChrysCapital has acquired a controlling 70.68% stake in Novartis India Limited (NIL), a BSE-listed company previously held by Novartis AG. This acquisition marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector, aiming to transform Novartis India into a leading branded-generics platform. Novartis India will undergo a name and corporate identity change and has appointed Dr. Vikas Gupta as CEO and Managing Director to lead its next phase of growth.
2026-07-30 10:40:50
Private equity firm ChrysCapital has acquired a controlling 70.68% stake in Novartis India Limited (NIL) from Novartis AG. This marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector and signifies a new chapter for NIL, which will adopt a new name and corporate identity. Vikas Gupta has been appointed CEO and MD, alongside new independent directors, to lead NIL's growth trajectory in key therapeutic areas like pain management and gynecology.
2026-07-27 21:40:37
This article from OpenSecrets details the lobbyists employed by Novartis AG in 2017, highlighting that out of 84 named lobbyists, 66 (78.6%) had previous federal government experience, including one former member of Congress. It lists the lobbying firms and individual lobbyists working for Novartis, along with the number of filings associated with each. The firm Williams & Jensen engaged the most lobbyists for Novartis in 2017.
2026-07-27 13:40:38
This article from OpenSecrets details the lobbyists working for Novartis AG in 2022, including information on their hiring firms and whether they are part of the "revolving door" of former government employees. It lists 60 named lobbyists, with 47 (78.3%) having previous federal government experience. The report also highlights the total lobbying spending for Novartis AG as of April 2026, totaling $4.07 million.
2026-07-27 13:40:37
TD Cowen has reiterated its Hold rating on Novartis AG (NVS.US) and maintained its price target of $180. This indicates an analyst's view that the stock is expected to perform in line with the market, with the current valuation justifying the existing price.
2026-07-27 12:47:10
Argus Research has raised its target price for Novartis AG (NVS) to $170. The pharmaceutical company, based in Switzerland, focuses on immunology, neuroscience, oncology, and cardiovascular, renal, and metabolic therapies. Argus analyst Jasper Hellweg covers Growth Pharmaceutical, Medical Technology, and Financial Technology companies for the firm.
